MacroGenics
MGNX · Nasdaq · United States
Share price · MGNX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MGNX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 23 Oct 2026-38.0%
- 29 Sep 2026-7.1%
Nothing announced by MGNX that day or the session before.
- 28 Sep 2026+8.6%
Nothing announced by MGNX that day or the session before.
- 14 May 2026+20.6%
- 12 May 2026+19.3%
- 10 Mar 2026+45.3%
- 25 Feb 2026+11.0%
- 17 Dec 2025+19.3%
Nothing announced by MGNX that day or the session before.
Share of unusual movement by asset
For each asset, the share of MGNX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 42% |
| Sessions with no dated event | — | 58% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | PD-1 x CTLA-4Multispecific antibody | Indication not yet linked | |
| Phase 1 | ADAM9Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1 | HIV envelope gp120 x CD3Multispecific antibody | HIV | |
| Phase 1 | HIV envelope gp41 x CD3Multispecific antibody | HIV | |
| Phase 1 | CD123 x CD3Multispecific antibody | Acute Myeloid Leukemia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
July 2027 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $19M | $31M | $49M | $20M-$6.3M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $33M | $39M | $114M | —-$41M operating cash flow | report ↗ |
| 2026-Q1 | $21M | $35M | $67M | $37M-$36M operating cash flow | report ↗ |
| 2025-Q3 | $73M | $33M | $80M | —-$30M operating cash flow | report ↗ |
| 2025-Q2 | $22M | $41M | $131M | $36M-$47M operating cash flow | report ↗ |
| 2025-Q1 | $13M | $40M | $146M | $41M-$47M operating cash flow | report ↗ |
| 2024-Q3 | $111M | $41M | $180M | —$60M operating cash flow | report ↗ |
| 2024-Q2 | $11M | $52M | $84M | $56M-$44M operating cash flow | report ↗ |
| 2024-Q1 | $9.1M | $46M | $80M | $52M-$46M operating cash flow | report ↗ |
| 2023-Q3 | $10M | $30M | $90M | —-$35M operating cash flow | report ↗ |
| 2023-Q2 | $13M | $43M | $109M | —-$2.1M operating cash flow | report ↗ |
| 2023-Q1 | $25M | $46M | $224M | $38M-$13M operating cash flow | report ↗ |
| 2022-Q3 | $42M | $48M | $84M | $25M-$9.4M operating cash flow | report ↗ |
| 2022-Q2 | $26M | $52M | $21M | $41M-$49M operating cash flow | report ↗ |
| 2022-Q1 | $11M | $61M | $47M | $66M-$58M operating cash flow | report ↗ |
| 2021-Q3 | $16M | $50M | $191M | $53M-$15M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $150M | $147M | $57M | $19M-$81M operating cash flow | report ↗ |
MacroGenics reported FY2025 revenue of $149.5M, down 0.3% YoY, with R&D expenses of $147.2M, down 16.9% YoY. The company reported a net loss of $74.6M for the year and held $189.9M in cash, cash equivalents and marketable securities as of December 31, 2025.
Management affirmed cash runway guidance into late 2027 and highlighted upcoming pipeline milestones, including initial Phase 1 data for MGC026 in mid-2026, initial Phase 1 data for MGC028 in the second half of 2026, a Phase 2 LINNET update for lorigerlimab in mid-2026, and an IND submission for MGC030 planned for the third quarter of 2026. The company also noted the FDA’s partial clinical hold on the LINNET study, with no new patients being enrolled while the hold remains in effect.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $150M | $177M | $183M | $17M-$68M operating cash flow | report ↗ |
| 2023-FY | $59M | $167M | $101M | $2.3M-$78M operating cash flow | report ↗ |
| 2022-FY | $152M | $207M | $109M | $30M-$87M operating cash flow | report ↗ |
| 2021-FY | $77M | $215M | $123M | $51M-$144M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($129K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-30 | Kuriakose Emil · director | Award / grant (derivative) | 44,000 | — | — | Form 4 |
| 2026-10-30 | VASCONCELLES MICHAEL · director | Award / grant (derivative) | 44,000 | — | — | Form 4 |
| 2026-10-30 | Kuriakose Emil · director | Award / grant (derivative) | 7,500 | — | — | Form 4 |
| 2026-10-30 | VASCONCELLES MICHAEL · director | Award / grant (derivative) | 7,500 | — | — | Form 4 |
| 2026-10-06 | Bonvini Ezio · Sr VP, Research & CSO | Option exercise | 8,000 | $2.60 | $21K | Form 4 |
| 2026-10-06 | Bonvini Ezio · Sr VP, Research & CSO | Option exercise (derivative) | 8,000 | $2.60 | $21K | Form 4 |
| 2026-08-19 | Peters Jeffrey Stuart · Senior VP, GC, and Secretary | Open-market sale | 31,105 | $4.15 | $129K | Form 4 |
| 2026-08-17 | Bonvini Ezio · Sr VP, Research & CSO | Option exercise | 40,000 | $2.60 | $104K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 109 reporting institutions held 43.2M shares ($116.2M, 67.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 6,012,000 | $17.4M |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 2,963,559 | $8.6M |
| 3 | MILLENNIUM MANAGEMENT LLC | 2,794,357 | $8.1M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,653,853 | $7.7M |
| 5 | TWO SIGMA INVESTMENTS, LP | 2,527,829 | $7.3M |
| 6 | BANK OF AMERICA CORP /DE/ | 2,401,814 | $6.9M |
| 7 | MARSHALL WACE, LLP | 2,025,526 | $5.9M |
| 8 | RA CAPITAL MANAGEMENT, L.P. | 1,864,176 | $5.4M |
| 9 | WASATCH ADVISORS LP | 1,559,701 | $4.5M |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,208,775 | $3.5M |
| 11 | BlackRock, Inc. | 1,163,146 | $3.4M |
| 12 | D. E. Shaw & Co., Inc. | 1,058,424 | $3.1M |
| 13 | Connor, Clark & Lunn Investment Management Ltd. | 867,249 | $2.5M |
| 14 | CITADEL ADVISORS LLC | 782,618 | $2.3M |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 697,321 | $2.0M |